303 related articles for article (PubMed ID: 25998688)
1. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
3. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
4. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
6. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Yu Y; Wang J; Xia N; Li B; Jiang X
Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
[TBL] [Abstract][Full Text] [Related]
7. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
[TBL] [Abstract][Full Text] [Related]
9. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
10. Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.
Kawamoto M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Kawabe K; Onishi H; Nakamura M; Morisaki T
Anticancer Res; 2018 May; 38(5):2739-2748. PubMed ID: 29715094
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
12. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
Gu WJ; Liu HL
Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
[TBL] [Abstract][Full Text] [Related]
13. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
[TBL] [Abstract][Full Text] [Related]
14. Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
Kao YT; Hsu WC; Hu HT; Hsu SH; Lin CS; Chiu CC; Lu CY; Hour TC; Pu YS; Huang AM
Kaohsiung J Med Sci; 2014 Jul; 30(7):323-30. PubMed ID: 24924837
[TBL] [Abstract][Full Text] [Related]
15. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
Ahmmed B; Kampo S; Khan M; Faqeer A; Kumar SP; Yulin L; Liu JW; Yan Q
J Cell Physiol; 2019 Jul; 234(7):10680-10697. PubMed ID: 30628067
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
[TBL] [Abstract][Full Text] [Related]
17. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Wang JH; Lee EJ; Ji M; Park SM
Oncol Rep; 2018 Jul; 40(1):346-354. PubMed ID: 29767267
[TBL] [Abstract][Full Text] [Related]
20. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
